Creutzfeldt-Jakob disease is the most common form of human prion diseases. A 57-year-old woman was transferred to our Department from a local hospital, where she had been treated for two weeks due to ...consciousness disorders and convulsive epileptic attacks that progressed to refractory status epilepticus. Electroencephalography showed diffuse spike-wave complex discharges and development of nonconvulsive status epilepticus. The causes of metabolic encephalopathy and paraneoplastic syndrome were ruled out. A combination of clinical features and findings of diagnostic procedures including electroencephalography, biomarkers in the cerebrospinal fluid and magnetic resonance imaging suggested with great probability that the patient was affected with sporadic Creutzfeldt-Jakob disease.
Thrombolysis with intravenous recombinant tissue plasminogen activator (rtPA) is the first evidence based treatment for acute ischemic stroke, which aims to reduce the cerebrovascular lesion. At ...University Department of Neurology, Sestre milosrdnice University Hospital, Zagreb, thrombolytic therapy with intravenous rtPA (alteplase) (Actilyse) for acute ischemic stroke was introduced in 2004. We present our results referring to demographic, time logistics and clinical outcome data as part of SITS-MOST (Safe Implementation of Thrombolysis in Stroke - MOnitoring STudy) and compare them with the results from other centers in Croatia and all other participating centers. Up to now, 56 patients (61% of male and 39% of female, average age 67 years) have been treated at our department with intravenous rt-PA (0.9 mg/kg body weight, maximum 90 mg), with 10% of the dose given as a bolus followed by 60-minute infusion. Our experiences with thrombolytic therapy with intravenous rt-PA (alteplase) (Actilyse) for acute ischemic stroke confirm the safety and the efficacy of this therapy.
Creutzfeldt-Jakobova bolest je najčešći oblik prionske bolesti u ljudi. Prikazuje se slučaj bolesnice koja je prevezena u našu Kliniku iz manje bolnice, gdje je bila liječena dva tjedna zbog ...poremećaja stanja svijesti i konvulzivnih epileptičnih napadaja koji su progredirali do epileptičnog statusa koji je bio refraktoran na primijenjenu terapiju. Elektroencefalografija je prikazala difuzna izbijanja kompleksa šiljak-val i razvoj nekonvulzivnog epileptičnog statusa. Koristeći kombinaciju kliničkih značajka i nalaza dijagnostičkih pretraga uključujući elektroencefalografiju, biomarkere u cerebrospinalnoj tekućini i nalaze magnetske rezonance zaključeno je s velikom vjerojatnošću da se radi o sporadičnom obliku Creutzfeldt-Jakobove bolesti.
Tromboliza intravenskim rekombiniranim aktivatorom tkivnog plazminogena (rt-PA) je prvi dokazani učinkoviti način liječenja akutnog ishemijskog moždanog udara u svrhu smanjenja cerebrovaskularnog ...oštećenja. U Klinici za neurologiju Kliničke bolnice "Sestre milosrdnice", Zagreb, trombolitička terapija intravenskim rt-PA-om (alteplase) (Actilyse®) u bolesnika s akutnim ishemijskim moždanim udarom započela je 2004. godine. Predstavljamo naše dosadašnje rezultate, koji se odnose na demografske, vremenske i podatke o kliničkom ishodu bolesnika, prikupljene u sklopu SITS-MOST (Safe Implementation of Thrombolysis in Stroke - MOnitoring STudy) istraživanja. u svrhu usporedbe rezultata dobivenih u našem centru s rezultatima iz drugih centara Hrvatske i svijeta. Do sada je u našem centru trombolizom intravenskim rt-PA-om (0,9 mg/kg tjelesne težine, do maksimalno 90 mg). 10% doze primijenjene u bolusu, 90% doze u infuziju u trajanju od 60 minuta, liječeno 56 bolesnika (61% muškarci, 39% žene, prosječne životne dobi 67 godina). Naša iskustva u trombolitičkoj terapiji (alteplase) (Acrdyse®) u bolesnika sa akutnim ishemijskim moždanim udarom potvrđuju učinkovitost i sigurnost takvog načina liječenja.
